Phase II Study of cisplatin and everolimus in patients with metastatic or unresectable neuroendocrine carcinomas (NEC) of extrapulmonary origin

Trial Profile

Phase II Study of cisplatin and everolimus in patients with metastatic or unresectable neuroendocrine carcinomas (NEC) of extrapulmonary origin

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2017

At a glance

  • Drugs Everolimus (Primary) ; Cisplatin
  • Indications Neuroendocrine carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jan 2017 Planned End Date changed from 1 Jun 2017 to 1 Jan 2018.
    • 11 Jan 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jan 2018.
    • 11 Jan 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top